9 citations
,
November 2023 in “Pain Physician” ExoFlo is safe and effective for treating Complex Regional Pain Syndrome symptoms.
2 citations
,
September 2024 in “Expert Opinion on Drug Metabolism & Toxicology” Ritlecitinib is an effective new treatment for Alopecia Areata.
402 citations
,
August 2011 in “Cancer research” Prostate cancer cells can make their own androgens to activate the androgen receptor, and treatments like abiraterone may increase this ability, suggesting new therapies should target the entire steroid-making pathway.
2 citations
,
June 2023 in “Journal of cell science” Mutations in iRhom2 affect hair and skin in mice and are linked to esophageal cancer, with ADAM17 playing a crucial role.
June 2026 in “British Journal of Dermatology” Regional prescribing of ritlecitinib mostly follows national guidance, but psychological assessments and consistent scoring need improvement.
3 citations
,
August 2019 in “Journal of The American Academy of Dermatology” Clascoterone safely promotes hair growth similar to minoxidil.
4 citations
,
May 2023 in “Research Square (Research Square)” Cepharanthine can potentially treat gastric cancer by stopping tumor growth.
44 citations
,
March 2012 in “Fitoterapia” Germacrone from Curcuma aeruginosa may help treat conditions related to male hormones by blocking a specific enzyme.
August 2025 in “Frontiers in Pharmacology” [6]-Gingerdiol 3-monoacetate shows promise for treating T. whipplei infections.
1 citations
,
August 2020 Croton membranaceus root extract can change how drugs are processed in the body.
Newer retinoid drugs are effective for skin conditions but have significant side effects.
1 citations
,
July 2025 in “Clinical and Experimental Dermatology” Deucravacitinib led to full hair regrowth in a severe alopecia areata patient.
3 citations
,
July 2022 in “Brain and Behavior” The HtrA1L364P mutation causes brain dysfunction and blood vessel damage.
69 citations
,
October 2013 in “Journal of Clinical Psychopharmacology” Naltrexone did not significantly reduce hair pulling but improved cognitive flexibility.
December 2022 in “Scientific Reports” Compound 4 is a promising treatment for hair loss with low toxicity.
January 1975 in “NJEA Review” The drug showed promise in treating renal cell carcinoma with manageable side effects.
February 2023 in “Reactions Weekly” January 2015 in “International Journal of Nanomedicine” Anionic squarticles can effectively counteract amitriptyline overdose, improving survival rates.
51 citations
,
December 2006 in “Mammalian Genome”
91 citations
,
May 2005 in “The Journal of Clinical Endocrinology & Metabolism” A new mutation in the human glucocorticoid receptor reduces its function and causes resistance to glucocorticoids.
227 citations
,
April 2023 in “The Lancet” Ritlecitinib effectively treats alopecia areata and is well-tolerated.
17 citations
,
October 2024 in “Journal of the American Academy of Dermatology” Brepocitinib effectively reduces inflammation and improves symptoms in cicatricial alopecia with good safety.
168 citations
,
December 1986 in “Cancer Chemotherapy and Pharmacology” Epirubicin is as effective as doxorubicin for cancer treatment with less heart damage, but doesn't work on doxorubicin-resistant cancers.
August 2022 in “Nature Biotechnology” Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.
June 2026 in “Journal of health economics and outcomes research” Ritlecitinib is more effective and cheaper than baricitinib for treating severe alopecia areata.
January 2026 in “Journal of Dermatological Science” DcR3 helps heal wounds and regrow hair by changing macrophages to a repair-focused type.
1 citations
,
May 2025 in “Cytotechnology” Icariside II may help treat gastric cancer by stopping tumor growth.
October 2022 in “The Journal of Clinical Pharmacology” Men with early-onset hair loss have less cardiometabolic benefit from bromocriptine.
26 citations
,
September 2024 in “Perspectives in Clinical Research” Drug repurposing offers faster, cheaper drug development but faces challenges like safety, ethics, and funding.